Patients sue J&J for $800m for ‘hiding antibiotic side effects’
January 22, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Janssen, Johnson and Johnson, Levaquin, Margaret Hamburg, lawsuit, levofloxacin
Six users of Johnson & Johnson’s antibiotic Levaquin are to sue the company for up to $870 million, claiming the …
California hospital becomes first to prescribe digital pill
January 22, 2016Medical Communications california, digital health, digital pill, ingestible pill, proteus
Proteus Digital Health, the first company to have a ‘digital pill’ approved by the FDA, has signed its first deal …
FDA approves new Kyprolis combo for multiple myeloma
January 22, 2016Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma
Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …
Merck appoints Jessie English to lead discovery team
January 22, 2016Research and Development Jessie English, Merck
Merck has appointed Jessie English as the new vice president of discovery, translational innovation platform immuno-oncology, effective February 16, 2016. …
NICE ‘yes’ for BMS skin cancer drug Opdivo
January 22, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer
NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …
Martin Shkreli subpoenaed in US to testify over drug pricing
January 21, 2016Medical Communications, Sales and Marketing Daraprim, Howard Schiller, Martin Shkreli, Valeant, turing
Former pharma chief exec Martin Shkreli has been issued with a subpoena by the US House of representatives, compelling him …
UK Pfizer boss criticised for NHS conflict of interest
January 21, 2016Erik Nordkamp, Keep Our NHS Public, King's College Hospitals NHS Trsut, NHS, Pfizer, conflict of interest, privitisation
Anti-privatisation campaigners have called on a London NHS hospital trust to revoke its decision to appoint the head of Pfizer …
AbbVie/Roche’s venetoclax bags FDA Breakthrough Therapy Designation
January 21, 2016Sales and Marketing AbbVie, Breakthrough Therapy Designation, FDA, Roche, venetoclax
AbbVie and Roche’s cancer drug venetoclax has been granted Breakthrough Therapy Designation by the FDA in combination with rituximab for …
GSK ‘in discussions’ over $1 billion tech deal with Qualcomm
January 21, 2016Medical Communications GSK, beyond the pill, digital pharma, joint venture, qualcomm
GlaxoSmithKline and telecoms giant Qualcomm are reportedly discussing a joint venture agreement worth as much as $1 billion, as the …
Five charged in US for scheme to steal GSK secrets
January 21, 2016Research and Development China, GSK, employee theft, trade secrets
Five people have been charged in the US for a scheme to steal secrets from British drugmaker GlaxoSmithKline and then …
Pharma leads global call for action on antimicrobial resistance
January 21, 2016Manufacturing and Production, Research and Development Davos, Lord Jim O'Neill, Review on antimicrobial resistance, World Economic Forum, antibiotic resistance, antimicrobial resistance
More than 70 leading international pharmaceutical and biotechnology companies, as well as industry associations, have come together to call for …
MSD and GAVI agree Ebola vaccine deal
January 20, 2016Manufacturing and Production, Research and Development Ebola, GAVI, MSD, WHO
MSD and the global vaccine alliance Gavi have agreed a deal to provide 300,000 dosesof an Ebola virus vaccine, to …
Lilly awaits FDA review of new arthritis treatment
January 20, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, FDA, Incyte, NDA, baricitinib, lilly, new drug application, rheumatoid arthritis
Eli Lilly has submitted a new drug application (NDA) to the FDA for baricitinib as a treatment for moderate-to-severe rheumatoid …
Arzerra approved by US FDA for leukaemia
January 20, 2016Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application
The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …
J&J to cut up to 3,000 jobs in key business unit
January 20, 2016Manufacturing and Production, Research and Development Jobs, Johnson and Johnson, pharmajobs, redundancies
Johnson & Johnson has announced a restructuring of its medical devices business unit that could result in up to 3,000 …
French Health Minister criticises CRO’s slow response to clinical trial accident
January 19, 2016Manufacturing and Production, Research and Development Bial, Biotrial, Marisol Tourain, clinical trial
Days after the clinical trial accident that left one participant dead and five hospitalised with neurological problems, French Health Minister …
Bayer opens OTC drug plant in China
January 19, 2016Manufacturing and Production Bayer, China, OTC, TCM, Yunnan, over the counter, traditional Chinese medicine
Bayer has opened a new manufacturing plant to produce over-the-counter (OTC) drugs in China, as the German firm looks to …
Alzheimer’s drugs prescriptions rise six-fold in a decade
January 19, 2016Manufacturing and Production Alzheimer's, Alzheimer's disease, NHSIC, dementia, prescribing
The number of prescriptions dispensed in England for approved medicines to treat Alzheimer’s increased from 502,000 in 2004 to 3 …
Sobi launches new haemophilia treatment in UK
January 19, 2016Manufacturing and Production, Sales and Marketing elocta, haemophilia a, sobi
Swedish Orphan Biovitrum Ltd (Sobi) has launched its haemophilia A treatment Elocta (efmoroctocog alfa) in the UK, following its EU …
Merck appoints new executive board members
January 19, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck
Merck has appointed two new members to its executive board: Udit Batra (45), head of the Life Science business sector, …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
